Mortality and Paclitaxel-Coated Devices
Top Cited Papers
- 9 June 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Cell Metabolism
- Vol. 141 (23), 1859-1869
- https://doi.org/10.1161/circulationaha.119.044697
Abstract
Background: Paclitaxel-containing devices (PTXDs) significantly reduce reintervention in patients with symptomatic femoropopliteal peripheral artery disease. A recent aggregate-data meta-analysis reported increased late mortality in patients with peripheral artery disease treated with PTXDs. We performed an individual patient data meta-analysis to evaluate mortality. Methods: Manufacturers of US Food and Drug Administration–approved and commercially available devices in the United States provided deidentified individual patient data for independent analysis. Cox proportional hazards 1-stage meta-analysis models using intention-to-treat methods were used for the primary analysis. A secondary analysis of recovered missing vital status data was performed. The impact of control crossover to PTXDs, cause-specific mortality, and drug dose mortality were assessed. Results: A total of 2185 subjects and 386 deaths from 8 PTXD trials with 4-year median follow-up were identified. The primary analysis indicated a 38% (95% CI, 6% to 80%) increased relative mortality risk, corresponding to 4.6% absolute increase, at 5 years associated with PTXD use. Control and treatment arm loss to follow-up and withdrawal were 24% and 23%, respectively. With inclusion of recovered vital status data, the excess relative mortality risk was 27% (95% CI, 3%–58%). This observation was consistent across various scenarios, including as-treated analyses, with no evidence of increased risk over time with PTXDs. Mortality risk tended to be increased for all major causes of death. There were no subgroup differences. No drug dose–mortality association was identified. Conclusions: This individual patient data meta-analysis, based on the most complete available data set of mortality events from PTXD randomized controlled trials, identified an absolute 4.6% increased mortality risk associated with PTXD use.Keywords
This publication has 33 references indexed in Scilit:
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Long-Term Safety and Efficacy of Paclitaxel-Eluting Stents: Final 5-Year Analysis From the TAXUS Clinical Trial ProgramJACC: Cardiovascular Interventions, 2011
- Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trialsEuroIntervention, 2011
- Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: A post hoc analysis of the SPIRIT III randomized trialAmerican Heart Journal, 2009
- Lesion complexity determines arterial drug distribution after local drug deliveryJournal of Controlled Release, 2009
- Taxanes for breast cancer during pregnancy: a systematic reviewAnnals Of Oncology, 2009
- Survival MethodsCirculation, 2007
- Systematic reviews in health care: Assessing the quality of controlled clinical trialsBMJ, 2001
- Flexible smoothing with B-splines and penaltiesStatistical Science, 1996
- Confidence bands for a survival curve from censored dataBiometrika, 1980